Similar Mortality Among United States Veterans With Invasive and Noninvasive Pneumonia due to Group B
GBS
Streptococcus agalactiae
Veterans Affairs
community-acquired pneumonia
respiratory tract
sputum
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
30
09
2021
accepted:
27
01
2022
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
The nosology of noninvasive pneumonia due to group B We conducted a retrospective cohort study among Veterans Affairs (VA) healthcare users between 2008 and 2017. Using data from electronic health records, we identified patients who had blood or respiratory cultures that grew GBS and had invasive pneumonia or noninvasive pneumonia. We analyzed patient and infection characteristics associated with all-cause mortality, including among the subset of patients with cultures that were monomicrobial for GBS. Among 1791 patients with GBS pneumonia, 646 (36%) cases were invasive and 1145 (64%) were noninvasive. Among those, 535 and 424 cases of invasive and noninvasive pneumonia, respectively, had cultures that were monomicrobial for GBS. All-cause 30-day mortality among those with monomicrobial GBS pneumonia was 15% for both those with invasive and noninvasive disease, respectively. Increasing age, severity of illness, healthcare exposure in the previous 90 days, and polymicrobial infection with In this large cohort, even when considering cases for which GBS was the only pathogen recovered, >40% of GBS pneumonia cases were noninvasive. All-cause mortality was comparable for invasive and noninvasive pneumonia. These findings suggest that the burden of GBS pneumonia may be greater than previously recognized by surveillance of invasive GBS disease and may inform treatment and prevention efforts.
Sections du résumé
BACKGROUND
BACKGROUND
The nosology of noninvasive pneumonia due to group B
METHODS
METHODS
We conducted a retrospective cohort study among Veterans Affairs (VA) healthcare users between 2008 and 2017. Using data from electronic health records, we identified patients who had blood or respiratory cultures that grew GBS and had invasive pneumonia or noninvasive pneumonia. We analyzed patient and infection characteristics associated with all-cause mortality, including among the subset of patients with cultures that were monomicrobial for GBS.
RESULTS
RESULTS
Among 1791 patients with GBS pneumonia, 646 (36%) cases were invasive and 1145 (64%) were noninvasive. Among those, 535 and 424 cases of invasive and noninvasive pneumonia, respectively, had cultures that were monomicrobial for GBS. All-cause 30-day mortality among those with monomicrobial GBS pneumonia was 15% for both those with invasive and noninvasive disease, respectively. Increasing age, severity of illness, healthcare exposure in the previous 90 days, and polymicrobial infection with
CONCLUSIONS
CONCLUSIONS
In this large cohort, even when considering cases for which GBS was the only pathogen recovered, >40% of GBS pneumonia cases were noninvasive. All-cause mortality was comparable for invasive and noninvasive pneumonia. These findings suggest that the burden of GBS pneumonia may be greater than previously recognized by surveillance of invasive GBS disease and may inform treatment and prevention efforts.
Identifiants
pubmed: 35198653
doi: 10.1093/ofid/ofac051
pii: ofac051
pmc: PMC8860157
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac051Informations de copyright
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.
Références
Open Forum Infect Dis. 2018 Jun 08;5(6):ofy030
pubmed: 29977953
Scand J Infect Dis. 2000;32(4):377-84
pubmed: 10959645
JAMA Netw Open. 2019 Dec 2;2(12):e1918324
pubmed: 31880800
J Crit Care. 2018 Dec;48:237-242
pubmed: 30243204
Clin Infect Dis. 2020 Oct 23;71(7):1604-1612
pubmed: 31665249
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Arch Intern Med. 1982 Sep;142(9):1642-5
pubmed: 7052006
JAMA Netw Open. 2019 Jun 5;2(6):e195172
pubmed: 31173120
Arch Intern Med. 2000 Nov 27;160(21):3252-7
pubmed: 11088086
J Clin Microbiol. 2008 Sep;46(9):2906-11
pubmed: 18632904
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
JAMA Intern Med. 2019 Apr 1;179(4):488-489
pubmed: 30776057
Infect Control Hosp Epidemiol. 2021 Jun 04;:1-8
pubmed: 34085618
J Infect Dis. 2021 Oct 13;224(7):1170-1178
pubmed: 32188975
JAMA Intern Med. 2019 Apr 1;179(4):479-488
pubmed: 30776079
Eur J Clin Microbiol Infect Dis. 2004 Mar;23(3):168-73
pubmed: 14986167
Health Bull (Edinb). 1982 Mar;40(2):81-5
pubmed: 7045039
Clin Infect Dis. 2005 Sep 15;41(6):839-47
pubmed: 16107984
J Hosp Med. 2017 Oct 18;13(1):34-37
pubmed: 29073317
Public Health Rep. 2016 Nov;131(6):839-843
pubmed: 28123232
Clin Infect Dis. 2009 Jul 1;49(1):85-92
pubmed: 19480572